Completed PHASE1 INTERVENTIONAL 2-arm NCT01633723

Phase I Clinical Trial of DA-6886 in Healthy Male Subjects

A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects

Sponsor: Dong-A ST Co., Ltd.

Conditions Irritable Bowel Syndrome

Interventions DA-6886 Placebo of DA-6886

Updated 7 times since 2017 Last updated: Apr 13, 2021 Started: Aug 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Irritable Bowel Syndrome, this trial is completed. The trial is conducted by Dong-A ST Co., Ltd. and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jan 2021 — May 2021 [monthly]

Unknown Status PHASE1

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dong-A ST Co., Ltd.

Data source: Dong-A ST Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea